Genetic testing firm Natera beats Q3 revenue estimates, raises 2025 revenue forecast

Natera

06/11/2025 21:35

Overview

Natera Q3 2025 revenue grows 34.7% yr/yr, beating analyst expectations

Company raises 2025 revenue guidance by $160 mln at the midpoint

Natera reports Q3 net loss of $87.5 mln due to higher operating expenses

Outlook

Natera raises 2025 annual revenue guidance to $2.18 bln - $2.26 bln

Company expects 2025 gross margin to be approximately 62% to 64%

Natera forecasts net cash inflow of approximately $100 mln for 2025

Result Drivers

PRODUCT REVENUE GROWTH - Driven by increased volume and average selling price improvements, as well as excess cash receipts for prior tests

TEST VOLUME INCREASE - Processed 15.2% more tests compared to Q3 2024, including record growth in oncology tests

GROSS MARGIN IMPROVEMENT - Higher revenues and reduced costs of test processing contributed to improved gross margins

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$592.20 mln
$512.75 mln (18 Analysts)
Q3 Net Income
-$87.50 mln
Q3 Income from Operations
-$97.60 mln
Q3 Operating Expenses
$482 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Natera Inc is $200.00, about 0% above its November 5 closing price of $199.92

Press Release: ID:nBw97FN1Wa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)